Effects of trimetazidine supplemented with meglumine adenosine cyclophosphate in the treatment of patients with VMC
Objective:To explore the effects of trimetazidine supplemented with meglumine adenosine cyclophosphate on peripheral blood T lymphocytes and myocardial enzymes in treating patients with viral myocarditis(VMC).Methods:80 patients with VMC admitted to the hospital from October 2020 to December 2021 were selected as the research subjects and they were randomly divided into control group and observation group,with 40 cases in each group.The control group was treated with meglumine adenosine cyclophosphate while the observation group was combined with trimetazidine on the basis of the control group.After 2 weeks of treatment,the clinical efficacy,cardiac function,serum T lymphocyte subsets levels,myocardial enzymes and occurrence of adverse reactions were compared between the two groups.Results:After 2 weeks of treatment,the clinical effective rate in observation group was higher compared with that in control group(P<0.05).The left ventricular ejection fraction and cardiac index in observation group were higher than those in control group(P<0.05).The levels of serum aspartate aminotransferase,creatine kinase and creatine kinase isoenzyme were lower in observation group compared to control group(P<0.05).The CD3+,CD4+ and CD4+/CD8+ in observation group were higher than those in control group(P<0.05)while the CD8+ was lower than that in control group(P<0.05).There were no statistical differences in the incidence rates of adverse reactions between the two groups during treatment(P>0.05).Conclusion:Trimetazidine supplemented with meglumine adenosine cyclophosphate has a significant clinical efficacy in the treatment of VMC,and it can help to reduce the myocardial enzymes,improve the cardiac function and enhance the immune function.
万方数据
维普
